Gilead Sciences Inc. (NYSE: GILD) is scheduled to report second quarter 2019 earnings results on Tuesday, July 30, after market close. Analysts
Earnings preview: What to look for when Gilead reports Q2 results
Categories
Biotechnology
AbbVie tops Q2 views; lifts FY19 earnings outlook
AbbVie's (NYSE: ABBV) earnings and revenue for the second quarter of 2019 surpassed Wall Street's estimates. AbbVie reported adjusted EPS of $2.26
Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also came in
AstraZeneca’s Q2 results beat market expectations
AstraZeneca Plc (NYSE: AZN) topped market estimates for revenue and earnings in the second quarter of 2019, giving shares a lift of
What to expect from AbbVie Q2 earnings
AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the market opens.
Earnings preview: Celgene deal in focus as Bristol-Myers prepares for Q2 results
Bristol-Myers Squibb (NYSE: BMY) will be releasing its quarterly results amid growing skepticism over the planned acquisition of rival drugmaker Celgene (CELG),
Earnings: Alexion Pharma Q2 results top expectations; raises FY19 guidance
Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% growth for its second-quarter earnings, helped by an increase in revenues. The results also topped
Is Advaxis exhausting its financial resources with the stock hitting a record low?
Advaxis Inc. (NASDAQ: ADXS) stock plunged to a record low of $1.54 on Tuesday as the late-stage biotech company has returned the
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them
Advaxis’ revenue declines in Q2 as Amgen terminaties collaboration agreement
Advaxis (NASDAQ: ADXS) reported that Q2 revenue decreased to $1.2 million from $1.7 million in the prior year quarter. The 32% decline
Immunogen Inc (NASDAQ: IMGN) Q1 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q1 2019 earnings call dated May 03, 2019 Corporate Participants: Sarah Kiely -- Director of Investor Relations Mark Enyedy -- President and Chief Executive Officer
Exelixis tops Q1 earnings and revenue estimates
Exelixis Inc. (NASDAQ: EXEL) surpassed Q1 earnings and revenue projections. The company reported earnings of $0.27 per share on revenue of $215.5
Novavax Q1 earnings preview: Future plans on ResVax and NanoFlu will be the key focus points
Novavax Inc (NASDAQ: NVAX) is slated to report its first quarter 2019 earnings results after market closes on Thursday. Novavax stock, which
Amgen Q1 earnings beat Street view; lifts full-year earnings guidance
Biotechnology firm Amgen (Nasdaq: AMGN) reported first-quarter earnings that increased from last year and exceeded estimates, while revenues remained unchanged. Meanwhile, the management
Fennec Pharma stock plunges to all-time low
Fennec Pharmaceuticals Inc. (FENC) stock plunged to an all-time low of $4.69 on Tuesday. Investors were concerned about the future of the
Aldeyra Therapeutics stock resumes trading, surges about 60% on positive trial results
After getting halted in Nasdaq for sometime, shares of Aldeyra Therapeutics (ALDX) resumed trading and climbed up about 60% during the pre-market
Cesca Therapeutics reports wider net loss for FY18 as sales fall
Cesca Therapeutics (KOOL) Monday reported a wider net loss for fiscal 2018 when revenues of the biotechnology firm declined sharply. The company’s
Cara Therapeutics stock surges after reporting Q4 earnings results
Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the fourth quarter
Earnings Preview Q4: Cara Therapeutics’ success in 2019 will depend on Korsuva trial outcomes
Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after the regular
Exelixis tops bottom and topline targets for Q4, stock rises
Exelixis (EXEL) reported Q4 earnings of 37 cents per share and revenue of $228.6 million that beat analysts' views. Analysts had expected
Four cheap biotech stocks to buy
In the current environment, investment in the biotech stocks could be a risky recommendation for the investors. Despite its erratic behavior, the